Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
It’s an AB-rated generic therapeutic version of Durezol
It plays a pivotal role in monitoring pharmaceutical pricing
A treatment to prevent extreme symptoms and cut hospitalisation
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Subscribe To Our Newsletter & Stay Updated
